Hip Pelvis.  2013 Jun;25(2):135-140. 10.5371/hp.2013.25.2.135.

Etanercept Treatment in Ankylosing Spondylitis Hip Lesions

Affiliations
  • 1Department of Orthopaedic Surgery, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Korea. moonsw1106@gmail.com

Abstract

PURPOSE
To evaluate the efficacy of etanercept in patients with an ankylosing spondylitis hip lesion.
MATERIALS AND METHODS
Between March 2008 and December 2011, this study evaluated 13 patients with hip lesions who were refractory to conventional therapy. The general improvement was evaluated by the Harris hip score, Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath AS Functional Index (BASFI), ESR, CRP, and complications.
RESULTS
The mean Harris hip score changed from 55.6+/-3.4 to 87.2+/-4.3(P=0.01). The mean BASDAI/ BASFI decreased from 6.8+/-1.7/6.8+/-1.6 before treatment to 4.4+/-1.8(P=0.02)/4.3+/-1.1(P=0.02) after treatment. The mean ESR/CRP changed from 48.4+/-31.5/5.8+/-5.1 to 20.8+/-19.7(P=0.06)/3.1+/-4.2(P=0.03). No complications were encountered.
CONCLUSION
These results suggest that etanercept can induce significant pain improvement in most ankylosing spondylitis hip lesions.

Keyword

Ankylosing spondylitis; Hip lesion; TNF antagonist; Etanercept

MeSH Terms

Baths
Hip
Humans
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Spondylitis, Ankylosing
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Full Text Links
  • HP
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr